Cystic Fibrosis
Conditions
Keywords
Cystic Fibrosis, Smoking, Vaping
Brief summary
In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population. Faced with a cohort of patients undergoing a complete transformation (improved quality of life and life expectancy, fewer hospitalizations, reduced respiratory symptoms, better social integration), it is becoming urgent to assess the current situation in order to optimize tobacco prevention. This is all the more important given the emergence of international studies objectively examining the interactions between smoking, vaping, and the efficacy of Kaftrio.
Interventions
None listed
Sponsors
University Hospital, Strasbourg, France
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patient (≥ 18 years old) * With confirmed cystic fibrosis * Regular follow-up at the Strasbourg Adult Cystic Fibrosis Center
Exclusion criteria
* Patients who have undergone a double lung transplant for cystic fibrosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of smoking in adults with cystic fibrosis | Up to 12 months | The proportion of adults with cystic fibrosis who smoke: Example: If 10 out of 100 adults with cystic fibrosis smoke, then the prevalence of smoking in this group is 10%. |
Countries
France
Contacts
Primary ContactRomain Kessler, MD, PhD
Outcome results
None listed